Depot Medroxyprogesterone Injection Market: By Type (Prescriptions & Generic Prescriptions), By End User (Hospital, Pharmacy, and others), By Application (Contraceptive, Hormone Replacement Therapy, Treatment of Endometriosis, and Others), and by Geography

Purchase Option

$ 4400
$ 6600
$ 8900

Depot Medroxyprogesterone Injection Market size was valued at USD 800.0 million in 2022 and is poised to grow at a significant CAGR of 4.0% from 2023 - 2029. The injectable progestin-only contraceptive depot medroxyprogesterone acetate (DMPA, often known as Depo-Provera) provides very effective, discreet, three-month reversible contraception. DMPA removes the necessity for daily user activity, action close to sexual intercourse, and partner collaboration. By legalizing the use of injectable contraceptives, developing countries are focusing on lowering infant and mother mortality rates. For example, Haryana was the first state in India to implement the use of injectable contraceptives. The project would start in nine districts across the state, with the injectable available for free at all district hospitals, primary health centers, and community health centers. The United Kingdom authorities authorized Sayana Press in 2015, a three-month progestin-only injectable contraception. The governmental and private partners declared at the London Summit that they would deliver around 12 million doses of Sayana Press to the world's poorest countries by 2020. Injections have traditionally been a popular method of contraception in Sub-Saharan Africa, and the introduction of the Sayana Press injection and Uniject device is expected to increase demand. The all-in-one prefilled injectable device increases access through non-clinical channels while improving safety. The unmet need for contraception remains high. An estimated 225 million women in developing countries would like to delay or prevent pregnancy but are not using any method of contraception. Common reasons include difficulty traveling to health facilities, social barriers, and lack of knowledge about available contraceptive methods. Developing countries are home to more significant population density; it is imperative that governments and local organizations play a pivotal role in creating awareness about family planning, thereby reducing the number of childbirths and population. This could potentially create a market opportunity for the players who offer contraceptive injections at affordable prices. Moreover, the growing demographic dividend in these regions and an increase in fertility rate will positively impact the contraceptive markets in general. It may present a lucrative opportunity for market players with greater market penetration and access to injectable formulations.

Recent Market Developments:

  • In January 2019, Drug firm Cipla received the final nod from the US health regulator for its Medroxyprogesterone injectable to prevent pregnancy. The company has received final approval from the United States Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Medroxyprogesterone injectable at 150mg/mL.

Depot Medroxyprogesterone Injection Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

4%

Largest Market

North America

Fastest Growing Market

Asia pacific
Depot Medroxyprogesterone Injection Market Dynamics

The growing demand for birth control measures and government attempts to raise awareness about various contraceptive methods are driving the market for Depot Medroxyprogesterone Injection. Various forecasting projects are underway to assess better the demand for Depot medroxyprogesterone acetate (DMPA) as a birth control method. For instance, The Concept Foundation hired the William Davidson Institute (WDI) in January 2015 to research DMPA demand in low- and middle-income nations. Manufacturers are now attempting to produce a subcutaneous low-dose injectable of medroxyprogesterone acetate to reduce some weight gain and metabolic side effects. On the other hand, DMPA has long been connected to various health problems, including osteoporosis, breast cancer, and a delayed return of fertility. In addition, long-term use of DPMA may result in a loss of bone mineral density; these factors restrain the depot medroxyprogesterone injection market.

Depot Medroxyprogesterone Injection Market Segmentation

By Type
  • Prescriptions
  • Generic Prescriptions
By Application
  • Contraceptive
  • Hormone Replacement Therapy
  • Treatment of Endometriosis
  • Other
By End User
  • Hospital
  • Pharmacy
  • Others

Frequently Asked Questions

The depot medroxyprogesterone injection market size was valued at USD 800.0 million in 2022

The depot medroxyprogesterone injection market key players are: Pfizer Inc. Fangtong Pharma. Co. Ltd Gador S.A. Sigma-Aldrich Co. LLC. Teva Pharmaceutical Industries Ltd. Greenstone LLC Serum Internation Ltd. West-Coast Pharmaceutical Arrow Pharma Group, Zuche Pharmaceuticals Pvt. Ltd.

The depot medroxyprogesterone injection market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
1. Executive Summary
2. Global Depot Medroxyprogesterone Injection Market Introduction 
2.1.Global Depot Medroxyprogesterone Injection Market  - Taxonomy
2.2.Global Depot Medroxyprogesterone Injection Market  - Definitions
2.2.1.Type 
2.2.2.Application
2.2.3.End Users
2.2.4.Region
3. Global Depot Medroxyprogesterone Injection Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID-19 on Market
4. Global Depot Medroxyprogesterone Injection Market Analysis, 2018 - 2022 and Forecast 2023 - 2029
4.1.  Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5. Global Depot Medroxyprogesterone Injection Market  By Type , 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
5.1. Prescriptions
5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Generic Prescriptions
5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
6. Global Depot Medroxyprogesterone Injection Market  By Application, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
6.1. Contraceptive
6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Hormone Replacement Therapy
6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Treatment of Endometriosis
6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
6.4. Other
6.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.4.3. Market Opportunity Analysis 
7. Global Depot Medroxyprogesterone Injection Market  By End Users, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
7.1. Hospital
7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Pharmacy
7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Others
7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
8. Global Depot Medroxyprogesterone Injection Market  By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Europe
8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Asia Pacific (APAC)
8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Middle East and Africa (MEA)
8.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
8.5. Latin America
8.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.5.3. Market Opportunity Analysis 
9. North America Depot Medroxyprogesterone Injection Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
9.1. Type  Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Prescriptions
9.1.2.Generic Prescriptions
9.2.  Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Contraceptive
9.2.2.Hormone Replacement Therapy
9.2.3.Treatment of Endometriosis
9.2.4.Other
9.3.  End Users Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Hospital
9.3.2.Pharmacy
9.3.3.Others
9.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.4.1.United States of America (USA)
9.4.2.Canada
10. Europe Depot Medroxyprogesterone Injection Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
10.1. Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Prescriptions
10.1.2.Generic Prescriptions
10.2.  Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Contraceptive
10.2.2.Hormone Replacement Therapy
10.2.3.Treatment of Endometriosis
10.2.4.Other
10.3.  End Users Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Hospital
10.3.2.Pharmacy
10.3.3.Others
10.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Germany
10.4.2.France
10.4.3.Italy
10.4.4.United Kingdom (UK)
10.4.5.Spain
10.4.6.Rest of EU
11. Asia Pacific (APAC) Depot Medroxyprogesterone Injection Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
11.1. Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Prescriptions
11.1.2.Generic Prescriptions
11.2.  Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Contraceptive
11.2.2.Hormone Replacement Therapy
11.2.3.Treatment of Endometriosis
11.2.4.Other
11.3.  End Users Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Hospital
11.3.2.Pharmacy
11.3.3.Others
11.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.China
11.4.2.India
11.4.3.Australia and New Zealand (ANZ)
11.4.4.Japan
11.4.5.Rest of APAC
12. Middle East and Africa (MEA) Depot Medroxyprogesterone Injection Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
12.1. Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Prescriptions
12.1.2.Generic Prescriptions
12.2.  Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Contraceptive
12.2.2.Hormone Replacement Therapy
12.2.3.Treatment of Endometriosis
12.2.4.Other
12.3.  End Users Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Hospital
12.3.2.Pharmacy
12.3.3.Others
12.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.GCC Countries
12.4.2.South Africa
12.4.3.Rest of MEA
13. Latin America Depot Medroxyprogesterone Injection Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
13.1. Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Prescriptions
13.1.2.Generic Prescriptions
13.2.  Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Contraceptive
13.2.2.Hormone Replacement Therapy
13.2.3.Treatment of Endometriosis
13.2.4.Other
13.3.  End Users Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Hospital
13.3.2.Pharmacy
13.3.3.Others
13.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Brazil
13.4.2.Mexico
13.4.3.Rest of LA
14. Competition Landscape
14.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
14.2.1.Pfizer Inc.
14.2.2.Fangtong Pharma. Co. Ltd
14.2.3.Gador S.A.
14.2.4.Sigma-Aldrich Co. LLC.
14.2.5.Teva Pharmaceutical Industries Ltd.
14.2.6.Greenstone LLC
14.2.7.Serum Internation Ltd.
14.2.8.West-Coast Pharmaceutical
14.2.9.Arrow Pharma Group,
14.2.10.Zuche Pharmaceuticals Pvt. Ltd.
15. Research Methodology 
16. Appendix and Abbreviations 
  • Pfizer Inc.
  • Fangtong Pharma. Co. Ltd
  • Gador S.A.
  • Sigma-Aldrich Co. LLC.
  • Teva Pharmaceutical Industries Ltd.
  • Greenstone LLC
  • Serum Internation Ltd.
  • West-Coast Pharmaceutical
  • Arrow Pharma Group,
  • Zuche Pharmaceuticals Pvt. Ltd.

Adjacent Markets